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Abstract 37 
Rationale: Malnutrition often affects elderly patients and significantly contributes to the reduction in 38 
healthy life expectancy, causing high morbidity and mortality. In particular, protein malnutrition is one of 39 
the determinants of frailty and sarcopenia in elderly people.  40 
Methods: To investigate the role of amino acid supplementation in senior patients we performed an open-41 
label randomized trial and administered a peculiar branched-chain amino acid enriched mixture (BCAAem) 42 
or provided diet advice in 155 elderly malnourished patients. They were followed for 2 months, assessing 43 
cognitive performance by Mini Mental State Examination (MMSE), muscle mass measured by 44 
anthropometry, strength measure by hand grip and performance measured by the Timed Up and Go (TUG) 45 
test, the 30 seconds Chair Sit to Stand (30-s CST) test and the 4 meters gait speed test. Moreover we 46 
measured oxidative stress in plasma and mitochondrial production of ATP and electron flux in peripheral 47 
blood mononuclear cells. 48 
Results: Both groups improved in nutritional status, general health and muscle mass, strength and 49 
performance; treatment with BCAAem supplementation was more effective than simple diet advice in 50 
increasing MMSE (1.2 increase versus 0.2, p=0.0171), ATP production (0.43 increase versus -0.1, p=0.0001), 51 
electron flux (0.50 increase versus 0.01, p<0.0001) and in maintaining low oxidative stress. The 52 
amelioration of clinical parameters as MMSE, balance, four meter walking test were associated to 53 
increased mitochondrial function. 54 
Conclusions: Overall, our findings show that sustaining nutritional support might be clinically relevant in 55 
increasing physical performance in elderly malnourished patients and that the use of specific BCAAem 56 
might ameliorate also cognitive performance thanks to an amelioration of mitochondria bioenergetics. 57 
Keywords 58 
Malnutrition, elderly patients, branched-chain amino acids, muscle mass and strength, mitochondrial 59 
activity and biogenesis, oxidative stress. 60 
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30-s CST, 30 seconds chair sit to stand test; ADL, activity of  daily living; BCAAem, branched chain amino 62 
acid enriched mixture; BCAAs, branched chain amino acids; BMI, body mass index; CIRS, cumulative index 63 
rating scale; COX-1 and 4, cytochrome C oxidase 1 and 4; FOXO, forkhead box O; GAPDH, glyceraldehyde 3-64 
phosphate dehydrogenase; GDS, geriatric depression scale; GLM, linear regression models; MFN-1 and 2, 65 
mitofusin-1 and 2; MMSE, mini-mental state examination; MNA, mini nutritional assessment test; mTOR, 66 
mechanistic target of rapamycin; NRF-1, nuclear respiratory factor-1; NO, nitric oxide; OECD, organisation 67 
for economic co-operation and development; PBMCs, peripheral blood mononuclear cells; ROS, reactive 68 
oxygen species; RT-PCR, real time PCR; TBARs, thiobarbituric acid reactive substances; TFAM, mitochondrial 69 
transcription factor A; TUG, timed up and go test. 70 
 71 
Introduction 72 
Thanks to an increased life expectancy, an improvement in health status and medical services, the older 73 
population is constantly increasing. In 2015, 617 million (8.5%) people in the world were aged 65 and over 74 
(older adults) and these numbers are estimated to rise to 1.6 billion by 2050 (1). Despite the increase in life 75 
expectancy, there is no corresponding increase in healthy life expectancy: recent findings in 2015 show 76 
that, despite a life expectancy at the age of 65 of 21.2 years for women and 17.9 years for men, only 9.4 77 
years are healthy years (2). Concomitantly, health maintenance in older age will be one of the most 78 
relevant societal challenges in the future years. Lifestyle changes appear to be fundamental in increasing 79 
healthy life expectancy, and adequate nutrition is enormously important, given that malnutrition (i.e., 80 
undernutrition), particularly as protein-energy deficit is very common amongst the elderly population. This 81 
is due to the effects of aging per se that causes decreased salivation, difficulty swallowing, and delayed 82 
emptying of the stomach and oesophagus, as well as slower gastrointestinal movement (3). Other 83 
conditions associated with aging, such as drug use, loneliness, depression, lack of oral health, low quality of 84 
life, in addition to chronic non-communicable diseases, markedly increase the undernutrition risk (4). It has 85 
been estimated that undernutrition affects between 20 and 50% of hospitalised patients (5) and 5 and 10% 86 
of patients living at home in the community (6), the great variations reported in different studies depends 87 
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not only to differences in the population analysed, but also on the adopted definition. Recently a large 88 
study (7), that applies harmonized criteria to define malnutrition in different clinical settings and 89 
population, shows a great underestimation of the problem and confirms higher prevalence of malnutrition 90 
in residents of nursing homes and hospitalized patients evaluated by Mini Nutritional Assessment test 91 
(MNA). Malnutrition is more prevalent in patients affected by acute and chronic disorders with reduced 92 
functional status (7) and is associated with poor clinical outcomes and prognosis. Malnutrition is associated 93 
with reduced immune function, anaemia, impaired cognitive function, and higher hospitalisation rate and is 94 
a strong independent predictor of mortality [for a review, see A. Granic et al, 2018 (8)]. Malnutrition causes 95 
body weight loss and muscle atrophy, decreased muscle strength and function, impaired balance, and 96 
increased fall and fall-related injuries. The malnutrition-linked muscle atrophy accelerates transition to 97 
frailty (9) and has been considered as one of the determinants of sarcopenia (10,11). Importantly, 98 
sarcopenia is defined as low muscle mass, with defective muscle strength (also named dynapenia) and 99 
decline of physical performance (12) and is, per se, associated with increased morbidity and mortality (13). 100 
Although several guidelines and consensus documents on nutritional care of malnourished elderly subjects 101 
have been proposed (14), and protein needs established in the range from 0.8 g/kg/day (healthy adults) 102 
and up to 1.5 g/kg/day (in some cases even higher) according to age, disease and degree of protein 103 
depletion (15), the daily protein consumption in older subjects is often inadequate and undernutrition and 104 
sarcopenia are underestimated and considered as one of the factors of aging (4, 7). 105 
It has been suggested that the aging process significantly affects protein metabolism and enhances the 106 
muscle wastage that accompanies undernutrition and sarcopenia. Some studies show lower plasma 107 
concentrations of branched-chain amino acids (BCAAs) in elderly subjects (16,17), whereas others do not 108 
(18,19). This may be due to the increased first-pass splanchnic extraction of amino acids in older people, 109 
with a consequent decrease in delivery to the skeletal muscle tissue and availability for muscle tissue 110 
anabolism (20). Most kinetics studies show no difference in the ability of older subjects to retain and 111 
metabolise BCAAs (21–24). 112 
 6 
 
These observations suggest that the dietary requirement of proteins and essential amino acids is higher in 113 
the elderly than in young adults (25) and that an increased intake of a mixture of amino acids or essential 114 
amino acids can increase amino acid availability and result in the stimulation of muscle protein anabolism 115 
(26). 116 
A number of reports, including a recent well conducted meta-analysis concludes that dietary supplement of 117 
essential amino acids is more effective than non-essential amino acid or whole protein supplementations in 118 
malnourished patients (27). 119 
Notably, amino acid mixtures enriched in BCAAs have been shown to promote mitochondrial biogenesis 120 
and function, in addition to decrease oxidative stress via nitric oxide (NO) and mechanistic target of 121 
rapamycin (mTOR) signalling pathways in middle-aged mice (28). A more recent study has shown the 122 
stimulatory effect of leucine on mitochondrial respiration and ATP production in human macrophages (29).  123 
These results are important because mitochondrial dysfunction is a hallmark of the aging processes and 124 
age-related disorders, including sarcopenia and cognitive decline, are characterized by reduced 125 
mitochondrial mass and function [for a comprehensive review, see N. Sun et al, 2016 (30)]. Dietary 126 
supplementation of  BCAA-enriched mixtures (BCAAem) may contribute to slow-down mitochondrial 127 
decline and to ameliorate clinical status of malnourished elderly patients (31). 128 
The MATeR study thus aimed to evaluate the efficacy of a specific BCAAem compared to diet advice to 129 
promote mitochondrial function and improve clinical outcomes, particularly muscle and cognitive 130 
performance, in malnourished elderly community-dwelling subjects. 131 
 132 
Materials and methods 133 
Study design. 134 
We conducted a parallel, randomized, controlled, open-label trial to determine the efficacy of dietary 135 
BCAAem supplementation, as compared with diet advice, in the slow-down of both muscle and cognitive 136 
deficit in malnourished community-dwelling men and women aged 80 years or older. Randomisation was 137 
performed by computer generated tables to allocate treatments, with a simple randomization method; the 138 
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patients received a consecutive number after enrolment and were subsequently allocated to randomization 139 
list, according with Kim et al (32). The randomisation was carried out by the principal investigator, scientists 140 
performing lab measurement and statistical analyses were blind to treatment. 141 
The inclusion criterion was malnutrition defined as MNA lower than 17. The MNA test is composed of 18 142 
items that can be completed in less than 10 minutes. It provides a multidimensional assessment of senior 143 
patients nutritional status taking into account four domains: anthropometry, general status, dietary habits, 144 
and self-perceived health and nutrition states. Anthropometry includes the measurement of calf and arm 145 
circumferences, Body Mass Index (BMI), calculated after the measurement of weight and height, and 146 
questions about weight loss (4 items); general status comprehends 7 questions related to general health, 147 
medication and mobility; the assessment of dietary habits comprehends 5 questions on the number of 148 
meals, food and fluid intake and autonomy of feeding; 2 questions evaluate self-perceived health and 149 
nutrition states (33,34). 150 
Exclusion criteria were known malignancy, life expectancy of less than two months, heart failure (NYHA IV), 151 
end stage renal disease, liver cirrhosis (Child B-C), tube/percutaneous endoscopic gastrostomy feeding or 152 
parenteral nutrition, Mini-Mental State Examination (MMSE)≤18 and MNA>17. MMSE ≥ 18 identifies 153 
patients with mild form of cognitive impairment, those patients generally do not have problems in 154 
swallowing and are able to take drugs. We evaluated for inclusion 336 malnourished patients presenting to 155 
our out-patients service for a geriatric evaluation, the evaluation was done by expert geriatricians, of the 156 
evaluated patients 181 were excluded for presence of exclusion criteria; one hundred and fifty-five 157 
malnourished elderly patients living at home in the community and who were admitted to the outpatients’ 158 
department of our Unit were enrolled. Patients were evaluated at baseline and randomised to receive diet 159 
advice, summarised in an easy-to-use brochure for lay persons (77 patients) or to BCAAem supplements (78 160 
patients, Aminotrofic®, kindly supplied by Errekappa Euroterapici S.p.A. and Professional Dietetics S.p.A, 2 161 
sachets/day). Aminotrofic® is a BCAA enriched mixture, it contains Leucine (1,250 mg), Lysine (650 mg), 162 
Isoleucine (625 mg), Valine (625 mg), Threonine (350 mg), Cystine (150 mg), Histidine (150 mg), 163 
Phenylalanine (10 mg), Methionine (50 mg), Tyrosine (30 mg), Tryptophan (20 mg), Vitamin B 6 (0.1 mg), 164 
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Vitamin B1 (0.15 mg). We suggested the patients to take the BCAAem in the mid-morning and afternoon, 165 
regardless of food ingestion. In order to check the compliance we asked the patients to bring back at center 166 
the empty sachets at follow-up visit.  167 
Diet advice comprised general advice on the meaning and consequences of malnutrition and dietary 168 
recommendation based on the principle of "Food First" to maximize the patient nutritional intake from 169 
regular food and drink according with the ESPEN Guidelines on Enteral Nutrition for geriatric patients (35). 170 
According to the "Food First" approach we suggested the patients to increase the frequency of eating, 171 
maximize the nutrient and energy density of food and drink and fortify food with the addition of fats and 172 
sugars, suggested recommendations were given to the patients both orally by the physician and by the use 173 
of a brochure; provided dietary recommendations are summarized in the Supplementary Table 1. 174 
Period of patient enrolment: February 2013-September 2017. Patients were called back to the centre and 175 
all the measurements were performed after 1 and 2 months. 116 patients completed the study (60 treated 176 
with BCAAem and 56 with diet advice). In the BCAAem group, 2 patients died after the first month, 1 was 177 
admitted to hospital within the first month, 10 patients did not return for the month-1 visit and 5 patients 178 
did not return for the month-2 visit for personal reasons. In the diet advice group, 1 patient died during the 179 
first month, 2 patients did not return for the month-1 visit since they were hospitalised, 14 patients did not 180 
return for the month-1 visit and 4 patients for the month-2 visit for personal reasons, there were no 181 
collateral effects. Only data from patients with complete follow up were included in the statistical analyses 182 
(Fig. 1). 183 
Fig.1. Diagram of the study design. 184 
The diagram shows the study design and the number of patients at each visit in bold. The tests performed 185 
at each visit are specified. 186 
 187 
 9 
 
 188 
The main outcome measures were muscle mass, strength and performance and mitochondrial ATP 189 
production; secondary measurements were cognitive performance, nutritional status, health perceived 190 
status, mitochondrial biogenesis and activity in peripheral blood mononuclear cells (PBMCs). The 191 
measurements were carried out at baseline and after 1 and 2 months of treatment. 192 
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Clinical assessment. 193 
Global clinical assessment: Self-sufficiency was measured by assessing the Katz Index of Activity of  Daily 194 
Living (ADL), which evaluates overall performance in six functions: bathing, dressing, going to toilet, 195 
transferring, continence and feeding; cognitive performance was evaluated by MMSE that is a brief test 196 
used to routinely track cognitive changes in an individual both cognitively intact or with severe cognitive 197 
impairment over time. Patients’ mood was evaluated by the short form of Geriatric Depression Scale (GDS), 198 
the scale consists of 15 questions related to the patient’s mood answered "yes" or "no". The cut-off point 199 
adopted to define a patient as depressed is a GDS higher than 7 (36). Perceived health status was measured 200 
by asking the patients to answer the question "How is your health in general?". The patients’ answers: 201 
"very good", "good", "fair", "bad" or "very bad" were rated from 5 (Very good) to 1 (Very bad), although 202 
there is not yet full standardisation of the measurement of perceived health status across Organisation for 203 
Economic Co-operation and Development (OECD) Countries, here we used a standard health interview 204 
survey instrument used in the OECD Health Statistics 2007 (37), confirmed in OECD Health Statistics 2018 205 
(available on line at http://www.oecd.org/els/health-systems/health-data.htm) and accepted in Italy. The 206 
Cumulative Index Rating Scale (CIRS) was also recorded, this scale accounts for both the presence and the 207 
severity of co-morbidities (38). 208 
Nutritional status assessment: We assessed patients’ dietary intake using the PROGEO software (Progeo 209 
S.r.l., Italy), it provides an extensive food database and allows to record and to accurately estimate 210 
patients’ average nutritional intake. The Photo Intake tool helps patients to recognize the amount of food 211 
by the visual weight method, ingested showing pictures of food in 3 portions, food quantities can also be 212 
recorded as conventional standard units (spoon, glass, cup, etc.). The software provides a large food 213 
database and automatically displays patients’ average daily calories and nutrients intake. The interview was 214 
based on the recall method on 7 days making reference to the "standard week" as suggested by the 215 
manufacturer. The interview was done by geriatricians trained by a nutritionist. 216 
BMI was assessed by weighing patients by a precision scale and measuring their height using an altimeter 217 
wall, BMI was calculated as weight in kg/height in meters squared. Percentage of fat mass was measured 218 
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using a plicometer (Mahr GMBH Esslingen), the Pollock, Schmidt and Jackson’s formula on three sites 219 
(triceps, subscapular and abdomen) was applied (39,40). Skinfold thickness measurements were performed 220 
by trained staff according to standard technique: the skinfold thickness was measured by lifting a fold of 221 
skin and subcutaneous fat away from the underlying muscle and bone, the skinfold thickness was measured 222 
in duplicate with the plicometer. When a difference between the first and the second measurement 223 
exceeded 6 mm, a third measurement was taken. The plicometer is applied 1cm from the ridge of skin; take 224 
reading 3 seconds after application, to standardise any effects produced by deformation of tissues. The 225 
triceps skinfold was measured at the back of the left arm, midway between the acromial process of the 226 
scapula and the olecranon process of the ulna. The subscapular skinfold is picked up just under the lower 227 
angle of the scapular lifted horizontally below the tip of right scapula. The abdominal skinfold was lifted 228 
diagonal midway between umbilicus and right anterior superior iliac spine. 229 
Muscle mass, strength and performance: Appendicular muscle mass was measured using arm and calf 230 
circumference. Arm circumference was measured in duplicate to the nearest 0.001 m at a point midway 231 
between the lateral projection of the acromion process of the scapula and the inferior margin of the 232 
olecranon process of the ulna. The mean of the two measurements was used in the analyses. The calf 233 
circumference was measured to the nearest 0.001 m on the left leg with the participant standing straight, 234 
feet 20 cm apart, body weight equally distributed on both feet and at the level of the widest circumference 235 
of the calf; measurements were taken according to the Longitudinal Aging Study Amsterdam (LASA - 236 
http://www.lasa-vu.nl/themes/physical/anthropometry.htm). 237 
Muscle strength was measured via the hand grip test, using a hydraulic hand dynamometer (MSD, Europe) 238 
(41) to assess muscle performance and mobility the Timed Up and Go (TUG) test, 30 seconds Chair Sit to 239 
Stand (30-s CST) test and the 4 meters gait speed test were performed. 240 
TUG is a simple test used to assess a person's mobility and requires both static and dynamic balance. TUG is 241 
performed by measuring the time that the patient takes to rise from a chair, walk three meters, turn 242 
around, walk back to the chair and sit down. TUG performed in ten seconds or less indicate normal 243 
mobility; 11–20 seconds are within normal limits for frail, elderly and disabled patients and greater than 20 244 
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seconds means that the person needs assistance outside and indicates further examination and 245 
intervention. A score of 30 seconds or more suggests that the person may be prone to falls (42). The 30-s 246 
CST allows the evaluation of lower body strength and to assess the fatigue effect due to the number of sit-247 
to-stand repetitions. It is performed with a chair without arms, the patient seated in the middle of the chair 248 
with the arms crossed over his/her chest, then is instructed to stand up as quickly as possible safely without 249 
using his/her arms. The number of stands the patients completed in 30 seconds is manually recorded (43). 250 
The 4-meter gait speed test was performed using a stopwatch and measures the time, in seconds, the 251 
patients take to complete a 4-meter walk. 252 
The risk of falls further was evaluated using the Tinetti Gait and Balance Instrument as follows: to test the 253 
patient’s balance, the patient has to sit in a hard, armless chair and is asked to rise and stay standing, then 254 
turn 360° and sit back down. Next, the patient walks a few meters at a normal speed, turns, walks back and 255 
sits down. The evaluator observes several features and scores the patient’s performance: the higher the 256 
score, the better the performance. The maximum score for Gait is 12 points, while the maximum for 257 
Balance is 16 points, with a total maximum for the overall Tinetti Instrument of 28 points. Score 258 
Interpretation: <19 high risk of falls, 19-28 low risk of falls. 259 
Laboratory tests. 260 
Functional evaluation of mitochondrial activity: In order to isolate mitochondrial fractions, blood cells were 261 
washed twice in ice-cold PBS, then lysed in 0.5 mL buffer A (50 mMTris, 100 mMKCl, 5 mM MgCl2, 1.8 mM 262 
ATP, 1 mM EDTA, pH 7.2), supplemented with protease inhibitor cocktail III (Calbiochem), 1 mM PMSF and 263 
250 mMNaF. Samples were clarified by centrifuging at 650×g for 3 min at 4°C, and the supernatant was 264 
collected and centrifuged at 13000×g for 5 min at 4°C. This supernatant was discarded and the pellet 265 
containing mitochondria was washed in 0.5 mL buffer A and suspended in 0.25 mL buffer B (250 mM 266 
sucrose, 15 mM K2HPO4, 2 mM MgCl2, 0.5 mM EDTA, 5% w/v BSA). A 50 µL aliquot was sonicated and used 267 
for the measurement of protein content, as reported in Campia et al, 2009 (44); the remaining part was 268 
diluted to a protein concentration of 10 µg/µL and stored at −80°C until the use. The activity of Complex I–269 
III was measured on 10 µL of non-sonicated mitochondrial samples (44), suspended in 0.59 mL buffer C (5 270 
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mM KH2PO4, 5 mM MgCl2, 5% w/v BSA). Then 0.38 mL buffer D (25% w/v saponin, 50 mM KH2PO4, 5 mM 271 
MgCl2, 5% w/v BSA, 0.12 mM cytochrome c-oxidized form, 0.2 mM NaN3) was added for 5 min at room 272 
temperature. The reaction was started with 0.15 mM NADH and was followed for 5 min. The absorbance 273 
was read using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments, Winooski, VT). Results 274 
were expressed as nmol reduced cytochrome C/min/mg mitochondrial proteins. In each experimental set, 275 
the complex I inhibitor rotenone (100 µM) was added as an internal negative control. In the presence of 276 
rotenone, the electron flux was reduced to below 5%. 277 
The amount of ATP was measured on 20 µg of mitochondrial extracts using the ATP Bioluminescent Assay 278 
Kit (FL-AA, Sigma Aldrich Co., St. Louis, MO). Data were converted into nmol/mg mitochondrial proteins, 279 
using a previously set calibration curve. 280 
Under these experimental conditions, the rate of cytochrome C reduction, expressed as nmol cytochrome C 281 
reduced/min/mg cell protein, was dependent on the activity of both Complex I and Complex III. 282 
Real time PCR and assessment of mitochondria biogenesis and fusion: Real time PCR (RT-PCR)  was used to 283 
evaluate the mRNA levels of Cytochrome C Oxidase 1 and 4 (COX-1 and COX-4), Mitofusin-1 and 2 (MFN-1 284 
and MFN-2), Nuclear Respiratory Factor-1 (NRF-1) and Mitochondrial Transcription Factor A (TFAM) from 285 
whole blood nucleated cells. 286 
Red cells were lysed in all peripheral blood samples, total nucleated cells were collected and dissolved in 287 
TRIzol reagent (TRISure, Bioline Reagents Ltd, UK) and frozen at -80 °C until RNA extraction. RNA was 288 
isolated using chloroform extraction and subsequent isopropanol precipitation according to the 289 
manufacturer’s protocol. 1 g of RNA was reverse-transcribed to single-stranded cDNA using the SensiFAST 290 
cDNA Synthesis Kit (Bioline Reagents Ltd, UK). RT-PCR was performed using the SensiFAST SYBR Hi-ROX Kit 291 
(Bioline Reagents Ltd, UK). The housekeeping control gene was -actin, and gene expression was quantified 292 
using the 2-Ct method. The primers used (Invitrogen, California, USA) are shown in Supplementary Table 293 
2. 294 
All the lab experiments were performed in duplicate, data presented are averages of the duplicates. The 295 
coefficient of variation intra-operator  ranges between 0.03 and 1.00 for all the measurements. 296 
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Oxidative stress: To determine the oxidative stress level, we measured plasma thiobarbituric acid reactive 297 
substances (TBARs), as indicators of lipid peroxidation, using ELISA (TBARS Assay Kit, Cayman Chemical, MI, 298 
USA), according to the manufacturer’s protocol. 299 
Statistical analyses: The sample size was calculated on both clinical and lab outcomes; amongst clinical 300 
outcome muscle mass was used; in particular sample size provide an 85% power (p<0.05), 50 patients per 301 
group have to be enrolled to detect a difference (alpha error = 0.05) of at least 2% variation in muscle mass, 302 
based on a study on the effect of BCAAs administration on muscle mass and performance in humans (45). 303 
As the patients were old and frail we assumed a possible 35% of drop out at the follow-up. In order to 304 
calculate sample size for lab tests we considered as significant an increase of 1.5 fold in ATP production as 305 
shown by D’Antona et al with BCAAem in aged mice (28), data on ATP production in humans by PBMCs 306 
derives from Avis et al (46) based on this analyses sample size was calculated to provide 95% power 307 
(p<0.05) to detect a 1.5-fold difference in ATP production was 13 patients per group .  308 
All the analysed variables were tested for normality by the kurtosis test, TUG, 30-s CST, 4 meters walking 309 
test, TBARs, electron flux were non-Gaussian. 310 
To evaluate possible differences between patients treated with BCAAem or diet advice at baseline the 311 
patients were compare by one-way ANOVA for Gaussian variables and by the Mann-Whitney U test for 312 
non-Gaussian ones. Gender was compared amongst patients treated with BCAAem or diet adviceby χ2 test. 313 
The effect of treatment was evaluated per protocol using the two-way ANOVA for repeated measurements 314 
for Gaussian variables, non-Gaussian variables were evaluated after logarithmic transformation. To 315 
evaluate possible influences of mitochondrial function on muscle and cognitive performance six linear 316 
regression models (GLM) were fitted, between ATP and electron flux and TUG, 30-s CST, Tinetti and 4 317 
meters walking test, hand grip and MMSE, non-Gaussian variables were logarithmically transformed. 318 
SPSS 24.0 were used for the analyses and p<0.05 was considered statistically significant. Graphs were 319 
drawn using GraphPad 7.0 for Windows. 320 
Ethics Committee approval and consent to participate. 321 
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The study was approved by the Ethics Committee of our Hospital ("Comitato Etico Interaziendale A.O.U. 322 
Città della Salute e della Scienza di Torino - A.O. Ordine Mauriziano - A.S.L. TO1", protocol number 323 
0002637), in accordance with the ethical standards of the Declaration of Helsinki and its subsequent 324 
amendments. Informed consent was obtained from all individual participants included in the study. The full 325 
protocol is available upon request to the corresponding author. 326 
 327 
Results 328 
Patients treated with BCAAem or diet advice were comparable for all the clinical variables analysed, this 329 
excludes possible selection bias that could influence our results (Supplementary Table 3). Compliance to 330 
BCAAem was good, none of the patients have a compliance lower than 75%, the compliance ranges 331 
between 75% and 90%.  332 
Treatment significantly improves general health and cognitive performance. 333 
Patients’ general health measured by perceived health status equally improved in both treatment groups 334 
and significantly correlated with nutritional status (MNA: R=0.50, p<0.0001; fat percentage: R=0.26, 335 
p=0.005) at the end of the follow-up period. Also, the mood measured by GDS significantly improved. The 336 
level of independence was not significantly influenced by treatment. 337 
Patients’ overall cognitive performance measured by MMSE significantly improved in patients treated with 338 
BCAAem, not in patients treated with diet advice; MMSE significantly correlated with MNA (R=0.28, 339 
p=0.002) as well as GDS (R=-0.32, p<0.0001) at the end of the follow-up period (Table 1). 340 
Treatment significantly improves nutritional status. 341 
Patients adhered to the dietary recommendation as shown by the increased caloric intake. Caloric intake 342 
increased in both groups and was particularly consistent in the group treated with diet advice, where 343 
dietary recommendations were reinforced by the use of an easy-to-use illustrated brochure, in this group 344 
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also protein intake was significantly higher. During treatment, we observed a significant improvement in 345 
nutritional status measured by MNA, fat mass and BMI in both groups (Table 2).  346 
BCAAem treatment increases muscle mass, strength and performance. 347 
Muscle mass measured by calf and arm circumferences significantly increased in both groups as well as 348 
muscular strength measured by hand grip strength (Table 3). 349 
To evaluate whether muscular performance was influenced by treatment, we performed the TUG, the 30-s 350 
CST test to evaluate both performance and resistance to fatigue. Muscular performance improved with 351 
treatment as did muscle mass.  Risk of falls was measured using the Tinetti scale and the TUG,  mobility was 352 
measured using the 4-meter gait speed test, these tests improved equally in the two groups (Table 3).  353 
BCAAem improve bioenergetic capacity of PBMCs. 354 
Here we show that ATP production and electron flux significantly increased over time only in mitochondria 355 
from patients treated with BCAAem, and that BCAAem maintain oxidative stress at baseline values, 356 
whereas, in patients treated with diet advice, oxidative stress increased over time (Table 4). 357 
To model the relationship between mitochondria stimulation on PBMCs and effects of BCAAem or diet 358 
advice on muscular and cognitive performance we applied a linear regression approach. 359 
Our data showed that mitochondrial ATP production significantly predicts balance measured by Tinetti 360 
after 2 months of treatment and 4 meters walking test after 1 month of treatment (Table 5). MMSE is 361 
significantly predicted by ATP after 1 month and by electron flux after 2 months of treatment (Table 6). 362 
We also evaluated the effect of BCAAem treatment on some of the main mitochondrial biogenesis and 363 
fusion markers. Our data showed that treatment increases the expression of COX-1 and COX-4 and TFAM, 364 
whereas NRF-1 shows only a non-significant trend towards the increase, significant differences versus 365 
baseline levels were measured only in patients treated with BCAAem. The expression of  MFN-1 and MFN-2 366 
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was increased although not significantly by treatment; in the  BCAAem treated patients we observed an 367 
increased expression of these two molecules after one month of therapy  (Table 7). 368 
 369 
Discussion 370 
As life expectancy increases, adequate nutrition is fundamental for successful aging, here, we confirm that 371 
amelioration of nutritional status is associated with improvement in general health status, muscle and 372 
cognitive performance in old malnourished patients, and show that this may be due to an improvement of 373 
their mitochondrial bioenergetics profile and decreasing oxidative stress.  374 
Here we show that the diagnosis of malnutrition and its treatment, albeit using different approaches, is 375 
fundamental in improving patients’ general health and nutritional status. Indeed, in both our treatment 376 
groups, there was an improvement in MNA, and weight gain, however the increase in caloric and protein 377 
intake was higher in patients treated only with diet advice; the use of this approach instead of the use of an 378 
isonitrogenous mix of non-essential aminoacids with a double blind design may be considered as a 379 
limitation of the study, however the use of the "food first" approach underlines the role of the physician’s 380 
counselling in patients’ adherence to diet. Another possible limitation of the study is the use of a “non-381 
standard” recall method for diet evaluation, here we use a recall on the 7 days before the interview as our 382 
old patients usually follow a standard diet with little variation day by day, the evaluation of 7 days allow us 383 
to make a more comprehensive evaluation asking the patients “what is your usual meal (breakfast, lunch, 384 
dinner and snacks)? Do you change your meal during one week? If yes when and how during the previous 385 
week?”. The improvement in cognitive performance, measured by MMSE, was significant in patients taking 386 
BCAAem supplements: indeed, patients treated with BCAAem gain, on average, 1.2 points of MMSE. This 387 
result is in accordance with a previous study in a cohort of patients with severe chronic obstructive 388 
pulmonary disease. However, in this study, the increase in cognitive performance was associated with 389 
improved pulmonary gas exchange and there was no mechanistic explanation (47). The effect of the 390 
administration of  BCAAs in cognitive function was also previously assessed in severely brain damaged 391 
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patients with hepatic encephalopathy or traumatic brain injuries: in these patients, intravenous BCAAs 392 
improve consciousness, assessed using the Glasgow Coma Scale and performance, assessed using the 393 
Disability Rating Scale. However, no cognitive tests were performed in these studies and the underlying 394 
mechanism was not investigated (48–52). A mechanistic explanation has been provided by the study of 395 
animal models of brain injury, demonstrating the efficacy of dietary supplementation with BCAAs in 396 
promoting cognitive performance, by restoring hippocampal function, given that BCAAs act as glutamate 397 
and GABA precursors (53). In humans, a recent, very large retrospective study showed an association 398 
between serum level of isoleucine, leucine and valine with a lower risk of dementia. This study does not 399 
report any causal mechanism (54).  400 
Poor nutrition and, in particular, protein-energy deficit further accelerate the loss of muscle mass and 401 
function associated with age: sarcopenia (55,56). Sarcopenia increases the risk of falls, disability, frailty, loss 402 
of independence and death increasing healthcare costs (57,58). Here, we show that intervention on 403 
malnutrition can improve muscle mass and performance. In particular, we show an improvement in 404 
balance by the Tinetti balance test and the TUG test, with a consequent reduction of the risk of falls and 405 
fall-related injuries in a population with increased risk of falls (average TUG higher than 14 seconds). 406 
Treatment increases muscle performance, increasing mobility, and resistance to fatigue; the improved 407 
performance in the 4-meter gait speed test observed during treatment demonstrates an overall increase in 408 
health and the performance status of the patients according to previous study (62). Also, muscle strength 409 
measured using hand dynamometer increased in both treatment groups. 410 
Taken together, these data demonstrate that dietary intervention can counteract the decrease in physical 411 
and cognitive performance in old malnourished patients and that loss of muscle mass and function can be 412 
countered using an appropriate treatment strategy in a rapidly aging population. 413 
Several studies suggest a major role of mitochondrial dysfunction as a major contributor to aging and age-414 
related diseases [for a review, see Cedikova et al, 2016 (63)]. Mitochondrial biogenesis, ATP production and 415 
oxidative phosphorylation capacity decrease with aging and production of reactive oxygen species, 416 
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damaged mitochondrial DNA and protein increase [for a review, see Cedikova et al, 2016 (63)]. In this 417 
study, we further investigate the mechanisms underlying the better clinical effects obtained with the 418 
administration of  BCAAem, besides diet advice, by evaluating the treatment effects on mitochondrial 419 
function, biogenesis and fusion, as well as oxidative stress. In animal models, the administration of BCAAs 420 
has been shown to be effective in increasing the number and the function of mitochondria (28). In a small 421 
cohort of young healthy obese and non-obese subjects, the infusion of a mixture of aminoacids increased 422 
ATP production rates of muscular mitochondria in lean, but not in obese subjects (64). The increase in size, 423 
number and energy production of mitochondria that follows the administration of  BCAAem was associated 424 
with better muscle performance, on both at skeletal and cardiac muscle level in mice (28). Here we 425 
evaluated mitochondria from PBMCs, it has been previously shown that mitochondria isolated from 426 
skeletal muscle and from PBMCs have a similar bioenergetics profile and are associated with gait speed in 427 
older adults (65), as regards neurological tissues other authors measured mitochondrial function in PBMCs 428 
and correlates its reduction with neurodegeneration (66). According with these observations we show that 429 
mitochondrial activity measured using ATP production and electron flux increase is associated  with both 430 
cognitive and muscular performance amelioration in elderly patients; these data are particularly interesting 431 
as they suggest a possible non-invasive and reliable measure to follow up treatment outcomes. We show 432 
that the increase of TFAM, mitochondrial respiratory chain (COX-1 and COX-4) and mitofusin gene 433 
expressions correlate with an increase in ATP production and electron flux, and suggest that BCAAem 434 
treatment induces biogenesis, activity and fusion of mitochondria, stimulating at the end the bioenergetic 435 
capacity of PBMCs. 436 
Mitochondrial biogenesis and fusion are particularly increased after the first month of treatment. 437 
Afterwards, there is a plateau with no further increase, whereas mitochondrial activity increases during the 438 
entire follow-up period. This suggests that, after an increase in the number and fusion of mitochondria, the 439 
organelles maintain an increased function without any further increase in their number. 440 
Other than the effect on muscle mass and function, treatment of malnutrition is associated with improved 441 
general health. This may be due to better energy production associated with an increase in respiratory 442 
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chain activity and a decrease in oxidative stress, in an experimental model of progeroid aging characterised 443 
by increased DNA damage, boosting mitochondrial preserves mammalian health and increases longevity 444 
(67). 445 
 It is well known that oxidative damage is one of the components of aging: the increase in free radical 446 
production and the decrease in the defence against oxidative stress cause molecular alteration and 447 
functional decay; the free radical theory of aging suggests that oxidative stress is an important factor in 448 
age-associated diseases (68). Here, we show that BCAAem supplementation lowers the levels of oxidative 449 
stress in elderly patients. 450 
In conclusion, this study, for the first time, suggests that BCAAem treatment in old malnourished patients 451 
could be a good strategy able to ameliorate the bioenergetic capacity of PBMCs, this effect may partially 452 
explain the positive trend on muscle and cognitive performance in these patients. 453 
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 656 
Table 1. Global clinical assessment at baseline and follow-up according to treatment. 657 
The table shows multiple T-test and Two-way ANOVA for multiple measure results. Values are shown as 658 
mean ± SE and 95% CI of the difference between basal, 1 and 2 months of treatment. 659 
* Denotes differences between baseline and 1 month; ** Denotes differences between baseline and 2 660 
months; $ Denotes differences between 1 and 2 months; Significant values are in bold. 661 
 662 
 Perceived health status 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 3±0.1 -0.56 to -0.02* 2.9±0.1 -0.56 to -0.02* Time < 0.0001 
1 month 3.3±0.1 -0.5 to 0.02$ 3.2±0.1 -0.6 to -0.04$ Treatment 0.8437 
2 months 3.5±0.1 -0.8 to -0.3** 3.5±0.2 -0.8 to -0.3** Interaction  0.9300 
 MMSE2 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE  95% CI of 
difference 
Effect of p 
baseline 25.1±0.4 -1.1 to -0.04* 25.6±0.4 -0.2 to 0.8* Time 0.0139 
1 month 25.7±0.4 -0.8 to 0.2$ 25.3±0.5 -1.0 to 0.06$ Treatment 0.9422 
2 months 26±0.4 -1.4 to -0.3** 25.8±0.4 -0.7 to 0.4** Interaction  0.0171 
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 GDS3 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 6.1±0.3 -0.4 to 0.8* 6.0±0.4 -0.2 to 0.9* Time 0.0084 
1 month 5.9±0.4 -0.3 to 0.9$ 5.7±0.4 -0.3 to 0.8$ Treatment 0.7448 
2 months 5.6±0.4 -0.1 to 1.1** 5.4±0.3 0.01 to 1.2** Interaction  0.9184 
 ADL4 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 10.2±0.3 -0.2 to 0.4* 9.7±0.3 -0.2 to 0.5* Time 0.3569 
1 month 10.1±0.3 -0.2 to 0.5$ 9.5±0.3 -0.5 to 0.1$ Treatment 01130 
2 months 10.0±0.3 -0.1 to 0.6** 9.7±0.3 -0.3 to 0.30** Interaction  0.2294 
1Branched Chain Amino Acid Enriched Mixture; 2Mini-Mental State Examination; 3Geriatric Depression Scale; 663 
4
Activity of  Daily Living. 664 
665 
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 666 
Table 2. Patients’ nutritional status at baseline and follow-up according to treatment.  667 
The table shows multiple T-test and Two-way ANOVA for multiple measure results. Values are shown as 668 
mean ± SE and 95% CI of the difference between basal, 1 and 2 months of treatment. 669 
* Denotes differences between baseline and 1 month; ** Denotes differences between baseline and 2 670 
months; $ Denotes differences between 1 and 2 months; Significant values are in bold. 671 
 672 
 Caloric Intake (Kcal/day) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 1095±36 -137 to -15.8* 1042±29 -169 to -48* Time <0.0001 
1 month 1172±36 -80 to 42.4$ 1151±31 -168 to -47$ Treatment 0.9740 
2 months 1189±36 -156 to -34.1** 1259±38 -277 to -156** Interaction  0.0031 
 Daily protein Intake (g/Kg weight) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 0.85±0.02 -0.03 to 0.09* 0.87±0.02 -0.20 to -0.04* Time 0.0874 
1 month 0.83±0.02 -0.06 to 0.06$ 0.97±0.02 -0.04 to 0.08$ Treatment 0.0001 
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2 months 0.83±0.02 -0.03 to 0.09** 0.96±0.02 -0.14 to -0.02** Interaction  0.0007 
 MNA2 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference  
Effect of  p 
baseline 14.8±0.26 -0.03 to 0.09* 14.9±0.28 -0.16 to -0.04* Time <0.0001 
1 month 18.0±0.43 -0.06 to 0.06$ 17.8±0.38 -0.04 to 0.08$ Treatment 0.9057 
2 months 18.9±0.5 -0.03 to 0.09** 18.8±0.47 -0.14 to -0.02** Interaction  0.8366 
 Fat mass (%) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 18.8±0.94 -1.68 to 0.61* 20.2±0.88 -1.7 to 0.6* Time 0.0009 
1 month 19.3±0.92 -2.16 to 0.13$ 20.8±0.88 -1.6 to 0.7$ Treatment 0.1708 
2 months 20.3±0.94 -2.70 to -0.41** 21.2±0.88 -2.2 to 0.1** Interaction  0.6438 
 BMI3 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
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baseline 20.5±0.42 -1.42 to 0.10* 20.8±0.41 -1.38 to 0.14* Time 0.0010 
1 month 21.2±0.68 -0.92 to 0.60$ 21.5±0.42 -0.81 to 0.71$ Treatment 0.7239 
2 months 21.3±0.66 -1.57 to -0.05** 21.5±0.41 -1.43 to 0.09** Interaction  0.9482 
1Branched Chain Amino Acid Enriched Mixture; 2Mini Nutritional Assesment test; 3Body Mass Index. 673 
674 
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 675 
Table 3. Muscle mass, strength and performance at baseline and follow-up according to treatment.  676 
The table shows multiple T-test and Two-way ANOVA for multiple measure results. Values are shown as 677 
mean ± SE and 95% CI of the difference between basal, 1 and 2 months of treatment. 678 
* Denotes differences between baseline and 1 month; ** Denotes differences between baseline and 2 679 
months; $ Denotes differences between 1 and 2 months; Significant values are in bold. 680 
 Muscle mass 
 Calf circumference (cm) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 30.4±0.35 -1.14 to -0.04* 30.7±0.43 -1.08 to 0.02* Time 0.0004 
1 month 31.0±0.38 -0.87 to 0.23$ 31.2±0.40 -0.54 to 0.56$ Treatment 0.8560 
2 months 31.3±0.39 -1.45 to -0.36** 31.19±0.39 -1.07 to 0.03** Interaction  0.4521 
 Arm circumference (cm) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 22.7±0.36 -0.75 to 0.23* 23.0±0.40 -0.83 to 0.15* Time 0.0045 
1 month 23.0±0.37 -0.77 to 0.21$ 23.3±0.40 -0.54 to 0.44$ Treatment 0.6754 
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2 months 23.3±0.38 -1.03 to -0.04** 23.4±0.44 -0.88 to 0.10** Interaction  0.7351 
 Muscle strength 
 Hand grip (Kg) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference  
Effect of  p 
baseline 17.9±1.0 -2.01 to 0.47* 17.9±1.0 -1.84 to 0.65* Time 0.0474 
1 month 18.5±1.0 -1.6 to 0.87$ 18.7±0.9 -1.0 to 1.50$ Treatment 0.7796 
2 months 18.3±1.0 -2.40 to 0.10** 19.1±1.0 -1.59 to 0.90** Interaction  0.5231 
 TUG (sec)2 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 19.8±2.14 1.5 to 7.6* 20.5±1.5 -1.2 to 4.9* Time 0.0001 
1 month 15.2±1.0 -2.9 to 3.2$ 18.7±1.6 -2.1 to 4.0$ Treatment 0.2780 
2 months 15.1±1.1 1.6 to 7.8** 17.7±1.7 -0.3 to 5.9** Interaction  0.3215 
 30-s CST3 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of Mean±SE 95% CI of Effect of  p 
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difference difference 
baseline 6.8±0.5 -2.6 to -0.7* 6.0±0.5 -2.4 to -0.5* Time <0.0001 
1 month 8.4±0.6 -1.0 to 0.88$ 7.4±0.5 -1.6 to 0.3$ Treatment 0.3328 
2 months 8.5±0.7 -2.7 to -0.7** 8.1±0.6 -3.0 to -1.1** Interaction  0.5810 
 Tinetti 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 20.4±0.8 -2.1 to -0.1* 18.3±0.8 -3.2 to -1.1* Time < 0.0001 
1 month 21.5±0.7 -1.7 to 0.3$ 20.4±0.8 -1.3 to 0.7$ Treatment 0.1503 
2 months 22.2±0.7 -2.8 to -0.8** 20.7±0.9 -3.4 to -1.4** Interaction  0.2076 
 4 meters walking test (sec) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 8.2±0.6 -0.3 to 1.7* 9.8±0.7 0.4 to 2.3* Time <0.0001 
1 month 7.5±0.6 -0.7 to 1.3$ 8.4±0.7 -0.6 to 1.4$ Treatment 0.1684 
2 months 7.2±0.6 0.04 to 2.0** 8.0±0.7 0.8 to 2.8** Interaction  0.3955 
1
Branched Chain Amino Acid Enriched Mixture; 
2
Timed Up and Go test; 
3
30 seconds Chair Sit to Stand test.681 
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 682 
Table 4. Mitochondrial activity and oxidative stress at baseline and follow-up according to treatment.  683 
The table shows multiple T-test and Two-way ANOVA for multiple measure results. Values are shown as 684 
mean ± SE and 95% CI of the difference between basal, 1 and 2 months of treatment. 685 
* Denotes differences between baseline and 1 month; ** Denotes differences between baseline and 2 686 
months; $ Denotes differences between 1 and 2 months; Significant values are in bold. 687 
 688 
 ATP (changes vs baseline) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 1.00±0.00 -0.45 to -0.15* 1.00±0.00 -0.13 to 0.17* Time 0.0001 
1 month 1.30±0.09 -0.28 to 0.016$ 0.98±0.01 -0.16 to 0.14$ Treatment 0.0005 
2 months 1.43±0.10 -0.58 to -0.28** 0.99±0.02 -0.14 to 0.16** Interaction  0.0001 
 Electron flux (changes vs baseline) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 1.00±0.00 -0.38 to -0.13* 1.00±0.00 -0.13 to 0.13* Time < 0.0001 
1 month 1.26±0.05 -0.37 to -0.12$ 1.00±0.01 -0.14 to 0.12$ Treatment < 0.0001 
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2 months 1.50±0.09 -0.62 to -0.38** 1.01±0.04 -0.14 to 0.12** Interaction      < 0.0001 
 TBARs2 (µg/M) 
 BCAAem1 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of  p 
baseline 2.3±0.4 -2.8 to 1.2* 4.1±0.7 -3.02 to 0.97* Time 0.0007 
1 month 3.0±0.57 -2.4 to 1.6$ 4.5±0.9 -4.61 to -0.61$ Treatment 0.0289 
2 months 3.2±0.70 -3.1 to 0.85** 6.7±1.3 -5.64 to -1.64** Interaction  0.0332 
1Branched Chain Amino Acid Enriched Mixture; 2Thiobarbituric Acid Reactive Substances. 689 
690 
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 691 
Table 5. Muscle performance and balance.  692 
The table shows the results for linear regression models (GLM), non-Gaussian variables indicated by * were 693 
logarithmically transformed. Significant values are in bold. 694 
 695 
Dependent variable Co-variate β±SE t p 95% CI 
Tinetti baseline Slope 18.9±2.7 7.0 0.000 13.5 to 24.4 
Electronflux baseline -0.02±0.01 -1.4 0.179 -0.05 to 0.009 
ATP baseline 0.05±0.03 1.5 0.134 -0.016 to 0.119 
Tinetti 1 month Slope 20.0±2.9 6.8 0.000 14.1 to 25.8 
Electronflux 1 month* 0.000±0.013 0.02 0.984 -0.03 to 0.26 
ATP 1 month 0.011±0.04 0.32 0.752 -0.06 to 0.08 
Tinetti 2 months Slope 48.9±13.5 3.6 0.001 21.8 to 75.9 
Electronflux 2 months* 0.05±0.04 1.5 0.131 -0.02 to 0.122 
ATP 2 months -13.5±6.2 -2.2 0.033 -25.9 to -1.1 
Dependent variable Co-variate β±SE t p 95% CI 
4 meters walking test 
baseline* 
Slope 0.89±0.08 11.2 0.000 0.7 to 1.0 
Electronflux baseline 0.000±0.000 0.8 0.394 0.000 to 0.001  
ATP baseline -0.001±0.001 -1.4 0.175 -0.003 to 0.001 
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4 meters walking test 1 
month* 
Slope 0.96±0.10 9.6 0.000 0.76 to 1.16 
Electronflux 1 month* 0.000±0.000 0.40 0.691 -0.001 to 0.001 
ATP 1 month -0.002±0.001 -2.0 0.045 -0.005 to -6.1E-5 
4 meters walking test 2 
months* 
Slope 0.42±0.46 0.92 0.361 -0.49 to 1.33 
Electronflux 2 months* -0.002±0.001 -1.73 0.089 -0.004 to 0.000 
ATP 2 months 0.23±0.21 1.08 0.283 -0.19 to 0.644 
 696 
Table 6. Cognitive performance.  697 
The table shows the results for linear regression models (GLM), non-Gaussian variables indicated by * were 698 
logarithmically transformed. Significant values are in bold.  699 
Dependent variable Co-variate β±SE t p 95% CI 
MMSE1 baseline Slope 24.3±1.4 17.2 0.000 21.5 to 27.2 
Electronflux baseline 0.002±0.007 0.22 0.829 -0.01 to 0.02 
ATP baseline 0.02±0.018 0.99 0.327 -0.02 to 0.05 
MMSE1 1 month Slope 22.7±0.17 12.9 0.000 19.2 to 26.20 
Electronflux 1 month* -0.002±0.08 -0.27 0.790 -0.02 to 0.013 
ATP 1 month 0.048±0.02 2.29 0.026 0.006 to 0.09 
MMSE1 2 months Slope 29.9±7.9 3.8 0.000 14.01 to 45.7 
Electronflux 2 months* 0.05±0.02 2.5 0.014 0.01 to 0.09 
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ATP 2 months -3.31±3.6 -0.9 0.366 -10.6 to 3.9 
    1Mini-Mental State Examination. 700 
701 
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 702 
Table 7. Mitochondria biogenesis and fusion at baseline and follow-up according to treatment. The table 703 
shows multiple T-test and Two-way ANOVA for multiple measure results. Values are shown as mean ± SE 704 
and 95% CI of the difference between basal, 1 and 2 months of treatment. 705 
* Denotes differences between baseline and 1 month; ** Denotes differences between baseline and 2 706 
months; $ Denotes differences between 1 and 2 months; Significant values are in bold. 707 
 708 
 COX-11 (changes vs baseline) 
 BCAAem2 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 1.0±0.0 -23.8 to -1.9* 1.0±0.0 -11.4 to 10.6* Time 0.1155 
1 month 13.9±8.5 -4.4 to 17.5$ 1.4±0.3 -13.2 to 8.7$ Treatment 0.1967 
2 months 7.3±3.6 -17.3 to 4.7** 3.7±1.2 -13.6 to 8.3** Interaction 0.1409 
 COX-43 (changes vs baseline) 
 BCAAem2 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 1.0±0.0 -2.3 to -0.10* 1.0±0.0 -1.39 to 0.76* Time 0.0459 
1 month 2.2±0.7 -0.7 to 1.47$ 1.3±0.09 -1.1 to 1.04$ Treatment 0.2373 
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2 months 1.8±0.5 -1.9 to 0.3** 1.3±0.19 -1.4 to 0.73** Interaction 0.3786 
 TFAM4 (changes vs baseline) 
 BCAAem2 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 1.0±0.0 -6.9 to -0.6* 1.0±0.0 -3.8 to 2.5* Time 0.0178 
1 month 4.8±1.0 -2.4 to 3.9$ 1.7±0.5 -4.5 to 1.8$ Treatment 0.0932 
2 months 4.2±1.15 -6.2 to 0.1** 3.0±1.5 -5.1 to 1.2** Interaction 0.2235 
 NRF-15 (changes vs baseline) 
 BCAAem2 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 1.0±0.0 -20.2 to 3.5* 1.0±0.0 -13.5 to 10.2* Time 0.6599 
1 month 9.4±6.4 -14.1 to 9.6$ 2.6±0.7 -12.8 to 10.9$ Treatment 0.3507 
2 months 11.6±9.5 -22.4 to 1.3** 3.6±1.2 -14.4 to 9.3** Interaction 0.2055 
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 MFN-16 (changes vs baseline) 
 BCAAem2 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 1.0±0.0 -22.4 to -2.1* 1.0±0.0 -10.8 to 9.4* Time 0.0746 
1 month 13.2±7.7 -7.0 to 13.3$ 1.7±0.3 -10.3 to 10.0$ Treatment 0.1648 
2 months 10.1±6.1 -19.3 to 1.0** 1.8±0.3 -11.0 to 9.3** Interaction 0.1320 
 MFN-27 (changes vs baseline) 
 BCAAem2 Diet advice Two-way ANOVA 
 Mean±SE 95% CI of 
difference 
Mean±SE 95% CI of 
difference 
Effect of p 
baseline 1.0±0.0 -11.6 to -1.1* 1.0±0.0 -6.0 to 4.5* Time 0.0772 
1 month 7.3±4.1 -1.9 to 8.6$ 1.7±0.3 -5.9 to 4.6$ Treatment 0.2046 
2 months 3.9±1.6 -8.2 to 2.3** 2.4±0.5 -6.6 to 3.9** Interaction 0.1810 
1Cytochrome C Oxidase-1; 2Branched Chain Amino Acid Enriched Mixture; 3Cytochrome C Oxidase- 4; 
4Mitochondrial Transcription Factor A; 5Nuclear Respiratory Factor-1; 6Mitofusin-1; 7Mitofusin-2. 
 
